Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2021 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
March 04, 2021 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics to Present at Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
February 08, 2021 08:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™

CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living...
January 13, 2021 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021

CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
December 17, 2020 07:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
December 08, 2020 17:00 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
December 03, 2020 21:02 ET | Source: Sigilon Therapeutics, Inc.

Sigilon Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living...